Paediatric Vaccinations
The ideal measure of efficacy, infection rates, is usually not studied as a primary endpoint because this requires large sample sizes. Surrogate measures such as immunogenicity are commonly used instead. Immunogenicity refers to the immune response induced by vaccination. Increased disease activity induced by vaccination and unintentional infections induced by live-attenuated pathogens in vaccines (especially in patients on high-dose immunosuppressive drugs). Another issue of vaccine safety is whether vaccines or their constituents can actually cause autoimmune disease (AID), which will be addressed briefly.
- Two doses of measles mumps rubella at 9 and 15 months of age, and no standalone measles vaccine at 9 months.
- Single dose administration of live attenuated H2 strain hepatitis A vaccine, or two doses of inactivated (killed) hepatitis A vaccine.
Related Conference of Paediatric Vaccinations
December 21-22, 2026
7th World Congress on Neuroimmunology and Neuroinfectious Diseases
Paris, France
Paediatric Vaccinations Conference Speakers
Recommended Sessions
- Immunopathogenesis
- Allergy, Asthma, and Immunology
- Animal & Plant-Derived Vaccines
- Child immunization and Vaccination Viral Immunology
- Clinical and Diagnostic Immunology
- Current research, and future challenges in vaccines
- DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines
- Geriatric Immunizations
- Human Vaccines-Infectious & non-Infectious
- Immunoinformatics
- Immunological Disorders
- Immunotoxicology
- Neuroendocrine Immunology
- Onco Immunology
- Paediatric Vaccinations
- Pathology and Immunology
- Psychoneuroimmunology
- Stem cell Immunology
- Vaccine & Immunization
- Vaccines against Drugs
Related Journals
Are you interested in
- Advances in Neuroimaging and Diagnostic Techniques - Neuroimmunology Congress 2026 (France)
- Advances in Neuroimmunology and Neuroinflammation - Neuroimmunology Congress 2026 (France)
- Artificial Intelligence and Data-Driven Approaches in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Autoimmune Neurological Disorders and Therapeutic Advances - Neuroimmunology Congress 2026 (France)
- Biomarkers and Precision Medicine in Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Case Studies and Clinical Practice in Neuroimmunology and Neuroinfectious Diseases - Neuroimmunology Congress 2026 (France)
- Clinical Trials and Drug Development in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- CNS Infections: Diagnosis, Management, and Prevention - Neuroimmunology Congress 2026 (France)
- Emerging Technologies and Future Directions in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Ethical Considerations and Future Perspectives in Neuroimmunology Research - Neuroimmunology Congress 2026 (France)
- Immunogenetics and Neuroimmune Interactions - Neuroimmunology Congress 2026 (France)
- Immunotherapy and Novel Treatment Strategies - Neuroimmunology Congress 2026 (France)
- Microbiome and the Gut-Brain-Immune Axis - Neuroimmunology Congress 2026 (France)
- Neurodegeneration and Immune System Interactions - Neuroimmunology Congress 2026 (France)
- Neuroimmunology in Pediatric Disorders - Neuroimmunology Congress 2026 (France)
- Neuroinfectious Diseases and Global Health Challenges - Neuroimmunology Congress 2026 (France)
- Public Health, Policy, and Global Collaboration in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Rehabilitation and Long-Term Management of Neuroimmune Disorders - Neuroimmunology Congress 2026 (France)
- Translational Research and Clinical Applications in Neuroimmunology - Neuroimmunology Congress 2026 (France)
- Young Researchers, Innovation, and Emerging Ideas - Neuroimmunology Congress 2026 (France)
